I think that is the plan. NP has mentioned getting as many options to phase 2 as possible, to me that would be for a buyout over a partnership deal in say the hiv indication. As many times as I have heard mention "Gilead analyst" with mono, I believe Gilead is the target. If mono gets approved it is worth billions in sales. Get mono pivotal going, get some cancer data, see if Gilead bites. My guess is they are following closely. I have seen buyout milestones based on future revenue. That would be one option if both sides can agree on what leronlimab is worth today, once we get the first evaluation in the billions (with either mono hiv or cancer).